AbbVie Inc. $ABBV Shares Acquired by Compagnie Lombard Odier SCmA

Posted by ABMN Staff on Apr 2nd, 2026

Compagnie Lombard Odier SCmA increased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 5.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 322,464 shares of the company’s stock after buying an additional 16,262 shares during the period. Compagnie Lombard Odier SCmA’s holdings in AbbVie were worth $73,680,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Diversified Trust Co boosted its holdings in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after purchasing an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new position in AbbVie in the third quarter valued at $720,000. Railway Pension Investments Ltd increased its stake in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors lifted its position in AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after buying an additional 9,811 shares during the period. Finally, Charles Schwab Trust Co boosted its stake in AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after buying an additional 15,502 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by insiders.

AbbVie Trading Down 1.3%

NYSE ABBV opened at $214.72 on Thursday. The stock has a market cap of $379.66 billion, a P/E ratio of 90.98, a PEG ratio of 0.76 and a beta of 0.38. The company’s fifty day simple moving average is $221.98 and its 200-day simple moving average is $224.58. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 EPS. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Analysts Set New Price Targets

A number of research analysts have recently commented on ABBV shares. Morgan Stanley upped their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. UBS Group decreased their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Finally, Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

Get Our Latest Stock Report on ABBV

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Federal tax-law effects: Analysts and reports show U.S. corporate cash taxes fell roughly $65B after recent tax changes, a trend benefiting large pharma cash flow and near-term free cash flow for companies like AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
Positive Sentiment: Allergan Aesthetics promotion: AbbVie’s aesthetics unit is running its fourth annual CoolMonth promotion (CoolSculpting offers), which can modestly boost procedure volumes and near-term aesthetics revenue. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
Neutral Sentiment: Earnings schedule: AbbVie set its Q1 2026 results release and conference call for April 29 (pre-market), a scheduled event that will be the next major catalyst for stock direction. AbbVie to Host First-Quarter 2026 Earnings Conference Call
Neutral Sentiment: Mixed intraday moves: Recent headlines show short-term intraday swings (some sessions with gains, others with underperformance versus the market), indicating investor attention is currently fragmented between fundamentals and newsflow. AbbVie Inc. stock rises Tuesday, still underperforms market AbbVie (ABBV) Gains As Market Dips: What You Should Know
Negative Sentiment: Litigation tied to Cerevel/AbbVie deal: A court ordered Pfizer and Bain to litigate a suit by Cerevel investors over the AbbVie transaction, creating deal-related legal uncertainty and potential distraction or liabilities. That legal cloud can pressure sentiment around transactions and M&A strategy. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
Negative Sentiment: Oncology headwinds: Analyst commentary flags likely 2026 revenue pressure in AbbVie’s oncology franchise — pricing pressure on Imbruvica and a near-term dip in legacy oncology sales could offset growth from newer oncology assets. This is a direct revenue-risk item investors care about for 2026 guidance. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.